Tekturna's Loss May Be Entresto's Gain As Novartis Hopes For Change In The ATMOSPHERE
This article was originally published in Scrip
Executive Summary
The negative outcome of Novartis AG's old blood pressure drug Tekturna in the ATMOSPHERE heart failure study highlights the strength of the company's new therapy Entresto.